Keloids: current prophylactic and therapeutic methods

Bienias, Wojciech; Kaszuba, Andrzej

doi:10.5114/pdia.2012.32392

Cited by 4 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TGF-β1, TGF-β2 and TGF-β3, all synthesized as inactive pro-peptides. The cytokine is multi-functional, yet it is believed to be the leading profibrotic factor in sclerotic disorders [ 11 – 13 ]. It interacts with extracellular matrix components, including fibrillin-1.…”

Section: Introductionmentioning

confidence: 99%

Transforming growth factor-β1 in plaque morphea

Dańczak‐Pazdrowska¹,

Kowalczyk²,

Szramka-Pawlak³

et al. 2013

pdia

View full text Add to dashboard Cite

IntroductionMorphea (localized scleroderma) is a rare cutaneous disease characterized by skin fibrosis of unknown pathogenesis. Transforming growth factor-β (TGF-β) is a potent profibrotic factor. The role of TGF-β in morphea remains unclear.AimThe goal of this study was to estimate the expression level of TGF-β1 in skin and peripheral blood mononuclear cells as well as the plasma levels of TGF-β1 in plaque morphea (MEP).Material and methodsThe study involved 20 MEP patients. Three control groups were involved: 1 – plasma: 36 healthy volunteers; 2 – PBMC: 47 healthy volunteers; 3 – skin biopsies: 13 samples collected during mastectomy (breast cancer was not skin involved). The analysis of TGF-β1 plasma levels was performed with the use an adequate ELISA kit, while real-time polymerase chain reaction was employed for the expression of TGF-β1 in peripheral blood mononuclear cells (PBMC) and skin.ResultsIn our study we have not detected differences in TGF-β 1 expression in PBMC, skin, nor in plasma levels of TGF-β1 between MEP patients and healthy controls, regardless of disease activity and its duration.ConclusionsThe results of our study contradict the claim of the substantial role of TGF-β1 in the most common morphea subtype – MEP.

show abstract

Section: Introductionmentioning

confidence: 99%

Transforming growth factor-β1 in plaque morphea

Dańczak‐Pazdrowska¹,

Kowalczyk²,

Szramka-Pawlak³

et al. 2013

pdia

View full text Add to dashboard Cite

show abstract

“…Differences and similarities between keloids and solid tumours. Since various studies mentioned the importance of investigating keloids from the perspective of benign and malignant tumours [2,46,47], in the following we briefly discuss this aspect by focusing on their differences and similarities. To start this discussion, we note that the word "cancer" appears to be coined by Hippocrates 2400 years ago, who compared the disease to a crab that adheres to its surroundings with its claws [48,49].…”

Section: Biological Aspects Of Keloid Disorders: Inflammation and Bio...mentioning

confidence: 99%

Modelling Keloids Dynamics: A Brief Review and New Mathematical Perspectives

Eftimie,

Rolin,

Adebayo

et al. 2023

Bull Math Biol

View full text Add to dashboard Cite

Keloids are fibroproliferative disorders described by excessive growth of fibrotic tissue, which also invades adjacent areas (beyond the original wound borders). Since these disorders are specific to humans (no other animal species naturally develop keloid-like tissue), experimental in vivo/in vitro research has not led to significant advances in this field. One possible approach could be to combine in vitro human models with calibrated in silico mathematical approaches (i.e., models and simulations) to generate new testable biological hypotheses related to biological mechanisms and improved treatments. Because these combined approaches do not really exist for keloid disorders, in this brief review we start by summarising the biology of these disorders, then present various 1 types of mathematical and computational approaches used for related disorders (i.e., wound healing and solid tumours), followed by a discussion of the very few mathematical and computational models published so far to study various inflammatory and mechanical aspects of keloids. We conclude this review by discussing some open problems and mathematical opportunities offered in the context of keloid disorders by such combined in vitro/in silico approaches, and the need for multi-disciplinary research to enable clinical progress.

show abstract

“…[1][2][3] Keloid incidents, in which estimated 15% to 20%, accounts for having been suffered by Afro-Americans, Hispanics, and Asians. 4,5 Keloid pathogenesis occurs as a result of longer inflammation and the increasing pro-duction of numerous growth factors such as Platelet Derived Growth Factor (PDGF), Transforming Growth Factor-β (TGF-β), and Vascular Endothelial Growth Factor (VEGF). Transforming Growth Factor-β (TGF-β) acts in fibroblast proliferation.…”

Section: Introductionmentioning

confidence: 99%

Is leukotriene B4 one of the keloid marker? a fibroblast keloid study

et al. 2019

View full text Add to dashboard Cite

Keloid pathogenesis occurs due to the duration of prolonged inflammatory phase and increased production of various growth factors such as TGF-β1 which may cause increasing fibroblast proliferation and collagen synthesis. Existence of one of the chemical mediators released during inflammation, leukotriene B4 (LTB4), in keloid pathogenesis specifically in the phases of inflammation and proliferation, is still unclear. The purpose of the study is to analyze the levels of LTB4 in keloid. Methods: Fibroblast culture that was done by explanting keloid and normal skin of a keloid patient. Measurement of LTB4 on keloid and normal fibroblast was done by Elisa method. This experiment was run in triplicate. Statistical test was conducted by t test for the unpaired data and Anova test. The experiment was done at cell culture laboratory of Medical Faculty of Padjadjaran University Bandung. Levels of LTB4 in keloid fibroblast was higher than that of normal skin fibroblast (mean 23143.27 vs 18191.85 pg/ml; p<0.05). Conclusion, increased LTB4 levels in keloid fibroblast showed the existence of LTB4 role in the prolonged inflammatory process in keloid pathogenesis.

show abstract

Keloids: current prophylactic and therapeutic methods

Cited by 4 publications

References 23 publications

Transforming growth factor-β1 in plaque morphea

Transforming growth factor-β1 in plaque morphea

Modelling Keloids Dynamics: A Brief Review and New Mathematical Perspectives

Is leukotriene B4 one of the keloid marker? a fibroblast keloid study

Contact Info

Product

Resources

About